Skip to main page content
Accesskeys
  • Page of 1
  1. Rawson RA, Obert JL, McCann MJ, Ling W. Psychological approaches for the treatment of cocaine dependence--a neurobehavioral approach. J Addict Dis. 1991;11(2):97-119. PubMed PMID: 1811763.
  2. Shoptaw S, Rawson RA, McCann MJ, Obert JL. The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis. 1994;13(4):129-41. PubMed PMID: 7734464.
  3. Rawson RA, Shoptaw SJ, Obert JL, McCann MJ, Hasson AL, Marinelli-Casey PJ, Brethen PR, Ling W. An intensive outpatient approach for cocaine abuse treatment. The Matrix model. J Subst Abuse Treat. 1995 Mar-Apr;12(2):117-27. PubMed PMID: 7623389.
  4. Obert JL, Rawson RA, Miotto K. Substance abuse treatment for "hazardous users": an early intervention. J Psychoactive Drugs. 1997 Jul-Sep;29(3):291-8. doi: 10.1080/02791072.1997.10400204. PubMed PMID: 9339862.
  5. Huber A, Lord RH, Gulati V, Marinelli-Casey P, Rawson R, Ling W. The CSAT methamphetamine treatment program: research design accommodations for "real world" application. J Psychoactive Drugs. 2000 Apr-Jun;32(2):149-56. doi: 10.1080/02791072.2000.10400223. PubMed PMID: 10908002.
  6. Freese TE, Obert J, Dickow A, Cohen J, Lord RH. Methamphetamine abuse: issues for special populations. J Psychoactive Drugs. 2000 Apr-Jun;32(2):177-82. doi: 10.1080/02791072.2000.10400226. PubMed PMID: 10908005.
  7. Galloway GP, Marinelli-Casey P, Stalcup J, Lord R, Christian D, Cohen J, Reiber C, Vandersloot D. Treatment-as-usual in the methamphetamine treatment project. J Psychoactive Drugs. 2000 Apr-Jun;32(2):165-75. doi: 10.1080/02791072.2000.10400225. PubMed PMID: 10908004.
  8. Obert JL, McCann MJ, Marinelli-Casey P, Weiner A, Minsky S, Brethen P, Rawson R. The matrix model of outpatient stimulant abuse treatment: history and description. J Psychoactive Drugs. 2000 Apr-Jun;32(2):157-64. doi: 10.1080/02791072.2000.10400224. PubMed PMID: 10908003.
  9. Obert JL, London ED, Rawson RA. Incorporating brain research findings into standard treatment: an example using the Matrix Model. J Subst Abuse Treat. 2002 Sep;23(2):107-13. Review. PubMed PMID: 12220608.
  10. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002 Sep;23(2):145-50. Review. PubMed PMID: 12220612.
  11. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004 Jun;99(6):708-17. doi: 10.1111/j.1360-0443.2004.00707.x. PubMed PMID: 15139869.
  12. Obert JL, Brown AH, Zweben J, Christian D, Delmhorst J, Minsky S, Morrisey P, Vandersloot D, Weiner A. When treatment meets research: clinical perspectives from the CSAT Methamphetamine Treatment Project. J Subst Abuse Treat. 2005 Apr;28(3):231-7. doi: 10.1016/j.jsat.2004.12.008. PubMed PMID: 15857723.
  13. Rawson RA, Gonzales R, Obert JL, McCann MJ, Brethen P. Methamphetamine use among treatment-seeking adolescents in Southern California: participant characteristics and treatment response. J Subst Abuse Treat. 2005 Sep;29(2):67-74. doi: 10.1016/j.jsat.2005.04.001. PubMed PMID: 16135335.
  14. Rawson RA, Gonzales R, Pearce V, Ang A, Marinelli-Casey P, Brummer J. Methamphetamine dependence and human immunodeficiency virus risk behavior. J Subst Abuse Treat. 2008 Oct;35(3):279-84. doi: 10.1016/j.jsat.2007.11.003. Epub 2008 Mar 7. PubMed PMID: 18329225; PubMed Central PMCID: PMC2630179.
  15. Harada T. [A new strategy for drug abuse treatment: the rationale and practice of the Matrix Model]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2010 Dec;45(6):557-68. PubMed PMID: 21387610.
  16. Perngparn U, Limanonda B, Aramrattana A, Pilley C, Areesantichai C, Taneepanichskul S. Methamphetamine dependence treatment rehabilitation in Thailand: a model assessment. J Med Assoc Thai. 2011 Jan;94(1):110-7. PubMed PMID: 21425736.
  17. Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W. Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med. 2012 Mar;6(1):68-76. doi: 10.1097/ADM.0b013e318233d621. PubMed PMID: 22105061; PubMed Central PMCID: PMC3276753.
  18. Harada T. [The randomized controlled trial of the prison-based Japanese Matrix Program (J-MAT) for methamphetamine abusers]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2012 Dec;47(6):298-307. PubMed PMID: 23461218.
  19. Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian J Psychiatr. 2015 Aug;16:17-25. doi: 10.1016/j.ajp.2015.05.036. Epub 2015 May 28. Review. PubMed PMID: 26123235.
  20. Gouse H, Magidson JF, Burnhams W, Remmert JE, Myers B, Joska JA, Carrico AW. Implementation of Cognitive-Behavioral Substance Abuse Treatment in Sub-Saharan Africa: Treatment Engagement and Abstinence at Treatment Exit. PLoS One. 2016;11(1):e0147900. doi: 10.1371/journal.pone.0147900. eCollection 2016. PubMed PMID: 26816208; PubMed Central PMCID: PMC4729488.
  • Page of 1